Neil J Mchugh

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8505311/neil-j-mchugh-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

120
papers

4,191
citations

h-index

62
g-index

5,276
ext. papers

4.2
avg, IF

L-index

#	Paper	IF	Citations
120	A Commercial Anti-TIF1ŒLISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing <i>Frontiers in Immunology</i> , 2022 , 13, 804037	8.4	Ο
119	Epidemiology of systemic sclerosis in the UK: an analysis of the Clinical Practice Research Datalink. <i>Rheumatology</i> , 2021 , 60, 2688-2696	3.9	2
118	Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models. <i>Scientific Reports</i> , 2021 , 11, 23335	4.9	2
117	Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. <i>Rheumatology</i> , 2021 , 60, 3398-3403	3.9	8
116	Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. <i>Journal of Rheumatology</i> , 2021 ,	4.1	3
115	Using Bayesian Networks to identify musculoskeletal symptoms influencing the risk of developing Psoriatic Arthritis in people with psoriasis. <i>Rheumatology</i> , 2021 ,	3.9	1
114	Preliminary Validation of the Severity of Nail Psoriasis Score (SNAPS) for the Assessment of Nail Psoriasis in Patients With Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021 , 6, 128-135	1.1	
113	Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. <i>Journal of Rheumatology</i> , 2021 , 48, 48-57	4.1	4
112	Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models. <i>Rheumatology</i> , 2021 , 60, 1891-1901	3.9	1
111	Comment on: The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity: reply. <i>Rheumatology</i> , 2021 , 60, e38	3.9	
110	Risk of Osteoarthritis in an Incident Cohort of People With Psoriatic Arthritis: A Population-based Cohort Study. <i>Journal of Rheumatology</i> , 2021 , 48, 841-846	4.1	
109	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. <i>Rheumatology</i> , 2021 , 60, 1588-1592	3.9	0
108	Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. <i>Journal of Rheumatology</i> , 2021 , 48, 1268-1271	4.1	1
107	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021 , 60, 2615-2628	3.9	12
106	Comment on: The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity: reply. <i>Rheumatology</i> , 2020 , 59, 2177-2178	3.9	O
105	The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 117	5.7	13
104	The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. <i>Rheumatology</i> , 2020 , 59, 2109-2114	3.9	35

Role of ANA and Myositis Autoantibodies in Diagnosis **2020**, 167-174

102	Newly Described Myositis Autoantibodies: HMGCR, NT5C1A, SAE, PUF60 2020 , 199-207		
101	Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. <i>Rheumatology</i> , 2020 , 59, 1026-1030	3.9	11
100	Evaluation of the Economic Burden of Psoriatic Arthritis and the Relationship Between Functional Status and Healthcare Costs. <i>Journal of Rheumatology</i> , 2020 , 47, 701-707	4.1	7
99	The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients. <i>Rheumatology</i> , 2020 , 59, 1626-1631	3.9	2
98	Autoantibodies in connective tissue disease. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020 , 34, 101462	5.3	4
97	Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA. <i>Rheumatology</i> , 2020 , 59, 1709-1714	3.9	2
96	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020 , 5, 12-22	1.1	3
95	Myositis autoantibodies: recent perspectives. Current Opinion in Rheumatology, 2020 , 32, 548-552	5.3	7
94	Longitudinal profiling of the gut microbiome in patients with psoriatic arthritis and ankylosing spondylitis: a multicentre, prospective, observational study. <i>BMC Rheumatology</i> , 2020 , 4, 60	2.9	1
93	Diagnosis and initial management in psoriatic arthritis: a qualitative study with patients. <i>Rheumatology Advances in Practice</i> , 2019 , 3, rkz022	1.1	1
92	Symptom-based stratification of patients with primary Sjgren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. <i>Lancet Rheumatology, The</i> , 2019 , 1, e85-e94	14.2	38
91	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 996-1002	2.4	48
90	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2019 , 58, 2162-2169	3.9	17
89	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sj\(\)gren\(\)s syndrome. RMD Open, 2019, 5, e000885	5.9	9
88	Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies. <i>Frontiers in Immunology</i> , 2019 , 10, 848	8.4	33
87	Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. <i>Journal of Autoimmunity</i> , 2019 , 101, 48-55	15.5	96
86	Psoriatic Nail Dystrophy Is Associated with Erosive Disease in the Distal Interphalangeal Joints in Psoriatic Arthritis: A Retrospective Cohort Study. <i>Journal of Rheumatology</i> , 2019 , 46, 1097-1102	4.1	7

О

85	Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis: Reply. <i>Rheumatology</i> , 2019 , 58, 2073-2074	3.9	2
84	Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. <i>Rheumatology</i> , 2019 , 58, 144-148	3.9	15
83	Gender stratified adjustment of the DAS28-CRP improves inter-score agreement with the DAS28-ESR in rheumatoid arthritis. <i>Rheumatology</i> , 2019 , 58, 831-835	3.9	3
82	The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. <i>Rheumatology</i> , 2019 , 58, 650-655	3.9	41
81	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019 , 46, 990-	995	26
80	The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort. <i>Rheumatology</i> , 2019 , 58, 468-475	3.9	14
79	Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis. <i>Rheumatology</i> , 2019 , 58, 269-273	3.9	9
78	A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud& Phenomenon. <i>Arthritis and Rheumatology</i> , 2018 , 70, 903-911	9.5	39
77	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2018 , 70, 1373-1384	4.7	38
76	Autoantibodies in myositis. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 290-302	8.1	136
75	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 563-570	2.4	31
74	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , 2018 , 57, 470-4	479	47
73	Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. <i>Rheumatology</i> , 2018 , 57, 712-717	3.9	26
72	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018 , 57, 370-381	3.9	36
71	Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 277-280	2.4	32
70	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 30-39	2.4	105
69	Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer. <i>Arthritis Research and Therapy</i> , 2018 , 20, 176	5.7	4
68	Response to: SAntisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteriaSby Cavagna. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e51	2.4	1

(2017-2018)

67	Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary SjgrenS syndrome: examination of data from the UK Primary SjgrenS Syndrome Registry. <i>Swiss Medical Weekly</i> , 2018 , 148, w14588	3.1	6
66	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 345-355	9.5	51
65	Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 343-347	2.4	24
64	Long-term effectiveness of tumour necrosis factor-Inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study. <i>Rheumatology Advances in Practice</i> , 2018 , 2, rky042	1.1	2
63	Exploring the illness representations of people with psoriatic arthritis: a secondary analysis of focus group data. <i>Rheumatology Advances in Practice</i> , 2018 , 2, rky023	1.1	3
62	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report. <i>Journal of Scleroderma and Related Disorders</i> , 2018 , 3, 249-252	2.3	25
61	Physical activity but not sedentary activity is reduced in primary Sjgren's syndrome. <i>Rheumatology International</i> , 2017 , 37, 623-631	3.6	10
60	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1522-1528	4.1	66
59	Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study. <i>Patient</i> , 2017 , 10, 455-462	3.7	27
58	Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients. <i>Journal of Rheumatology</i> , 2017 , 44, 488-492	4.1	39
57	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 673-680	2.4	138
56	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1207-1218	2.4	71
55	A rare coding allele in is protective for psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1321-1324	2.4	10
54	Presentation of SLE in UK primary care using the Clinical Practice Research Datalink. <i>Lupus Science and Medicine</i> , 2017 , 4, e000172	4.6	25
53	Biopsy pathology in a large cohort of juvenile dermatomyositis is heterogeneous and, for the most part, independent of autoantibody phenotype. <i>Canadian Journal of Neurological Sciences</i> , 2017 , 44, S6-S	s 6	
52	Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 701-707	2.4	95
51	Subjective and Objective Measures of Dryness Symptoms in Primary Sjgren's Syndrome: Capturing the Discrepancy. <i>Arthritis Care and Research</i> , 2017 , 69, 1714-1723	4.7	12
50	17. Anti-synthetase autoantibody is seen in patients with overlap myositis in the UK cohort of patients with Jveunile Dermatomyositis. <i>Rheumatology</i> , 2017 , 56,	3.9	1

49	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1774-1779	2.4	36
48	Transcriptional profiling identifies differential expression of long non-coding RNAs in Jo-1 associated and inclusion body myositis. <i>Scientific Reports</i> , 2017 , 7, 8024	4.9	25
47	Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort. <i>Journal of Autoimmunity</i> , 2017 , 84, 55-64	15.5	71
46	Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor. <i>Arthritis Care and Research</i> , 2017 , 69, 783-793	4.7	25
45	Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. <i>Rheumatology</i> , 2017 , 56, 2109-2113	3.9	38
44	Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 210	5.7	23
43	Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. <i>Rheumatology</i> , 2017 , 56, 603-612	3.9	15
42	Eligibility for clinical trials in primary Sjgrens syndrome: lessons from the UK Primary Sjgrens Syndrome Registry. <i>Rheumatology</i> , 2016 , 55, 544-52	3.9	7
41	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , 2016 , 18, 156	5.7	4
40	Replication of a distinct psoriatic arthritis risk variant at the IL23R locus. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1417-8	2.4	5
39	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1060-71	9.5	485
38	Novel Composite Radiographic Score for Longitudinal Observational Studies of Psoriatic Arthritis: A Proof-of-concept Study. <i>Journal of Rheumatology</i> , 2016 , 43, 367-70	4.1	3
37	Serological subsets of juvenile idiopathic inflammatory myopathiesan update. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 427-37	5.1	3
36	174 A Diagnostic and Treatment Challenge: The Prevalence and Clinical Associations of Anti-HMG-CoA Reductase Autoantibodies in a Large UK Juvenile-Onset Myositis Cohort. <i>Rheumatology</i> , 2016 , 55, i132-i133	3.9	2
35	Brief Report: Anti-Eukaryotic Initiation Factor 2B Autoantibodies Are Associated With Interstitial Lung Disease in Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2778-2783	9.5	21
34	Fatigue in primary Sjgren's syndrome is associated with lower levels of proinflammatory cytokines. <i>RMD Open</i> , 2016 , 2, e000282	5.9	46
33	Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials. <i>Journal of Rheumatology</i> , 2016 , 43, 1063-7	4.1	20
32	Implications of the diversity of class I HLA associations in psoriatic arthritis. <i>Clinical Immunology</i> , 2016 , 172, 29-33	9	12

(2014-2016)

31	Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 880-884	2.2	6	
30	Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary. <i>Journal of Rheumatology</i> , 2015 , 42, 1163-8	4.1	35	
29	Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. <i>Rheumatology</i> , 2015 , 54, 2010-4	3.9	45	
28	The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review. <i>Clinical Rheumatology</i> , 2015 , 34, 2089-95	3.9	18	
27	Estimating the diagnostic accuracy of rheumatoid factor in UK primary care: a study using the Clinical Practice Research Datalink. <i>Rheumatology</i> , 2015 , 54, 1882-9	3.9	5	
26	Verna Wright Lecture: Psoriatic Arthritis: The Need for Early Intervention. <i>Journal of rheumatology Supplement, The</i> , 2015 , 93, 10-3		6	
25	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015 , 6, 6046	17.4	103	
24	Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. <i>Rheumatology</i> , 2015 , 54, 157-62	3.9	46	
23	Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. <i>Rheumatology</i> , 2015 , 54, 915-26	3.9	49	
22	Serum soluble bone turnover biomarkers in psoriatic arthritis and psoriatic spondyloarthropathy. <i>Journal of Rheumatology</i> , 2015 , 42, 21-30	4.1	39	
21	Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History. <i>Journal of Rheumatology</i> , 2015 , 42, 1169-76	4.1	19	
20	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1882-5	2.4	49	
19	Reactivity in ELISA with DNA-loaded nucleosomes in patients with proliferative lupus nephritis. <i>Molecular Immunology</i> , 2015 , 68, 20-4	4.3	3	
18	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjgren& Syndrome. <i>PLoS ONE</i> , 2015 , 10, e0143970	3.7	24	
17	Health-related utility values of patients with primary SjgrenS syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1362-8	2.4	63	
16	Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. <i>Rheumatology</i> , 2014 , 53, 2204-8	3.9	106	
15	Arthritis in idiopathic inflammatory myopathy: clinical features and autoantibody associations. <i>Journal of Rheumatology</i> , 2014 , 41, 1133-9	4.1	18	
14	Polymorphisms in IL-1B distinguish between psoriasis of early and late onset. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 1459-1462	4.3	19	

13	Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1206-11	4.1	12
12	Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2014 , 16, R138	5.7	118
11	Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1504-9		52
10	Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1358-61	2.4	109
9	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 986-91	2.4	192
8	The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. <i>Rheumatology</i> , 2013 , 52, 1754-7	3.9	72
7	The ClASsification for Psoriatic ARthritis (CASPAR) criteriaa retrospective feasibility, sensitivity, and specificity study. <i>Journal of Rheumatology</i> , 2012 , 39, 154-6	4.1	96
6	Genetic association study of NF- B genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2012 , 51, 794-9	3.9	26
5	Work disability in psoriatic arthritis: a systematic review. <i>Rheumatology</i> , 2012 , 51, 275-83	3.9	74
4	Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. <i>Arthritis Research and Therapy</i> , 2011 , 13, 209	5.7	77
3	Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1016-9	2.4	60
2	Traditional schemes for treatment of psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , 2009 , 83, 49-51		
1	Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. <i>Rheumatology</i> , 2009 , 48, 607-12	3.9	221